MedTrace Logo

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

NCT03132493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 676

Last updated 2018-11-14

No results posted yet for this study

Summary

The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab.

A standard anonymous data collection form will be used to collect data and to analyze it.

Patients with advanced Non-Small Cell Lung Cancer previously treated and included in the SPANISH expanded access programme of nivolumab.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Nivolumab 10 MG/ML

nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression

Sponsors & Collaborators

  • Spanish Lung Cancer Group

    lead OTHER

Principal Investigators

  • Delvys Rodríguez, MD, PhD · Hospital Universitario Insular de Gran Canaria

  • Margarita Majem, MD, PhD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2017-12-01
Completion
2018-09-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03132493 on ClinicalTrials.gov